In a pregnant woman with a history of genital herpes simplex virus (HSV) infection and no recent lesions, should she start suppressive antiviral therapy if her partner experiences an outbreak?

Should a Pregnant Woman with HSV History Start Suppressive Therapy if Her Partner Has an Outbreak?

No, suppressive antiviral therapy is not routinely recommended for pregnant women with a history of genital herpes who have no recent outbreaks, even if their partner experiences an outbreak. The primary concern in pregnancy is maternal viral shedding at delivery, not partner outbreak status.

Clinical Reasoning

The available guideline evidence specifically addresses this scenario. Suppressive therapy during pregnancy is not used routinely 1. The guidelines state clearly that "episodic therapy for first-episode HSV disease and for recurrences can be offered during pregnancy, but suppressive therapy is not used routinely" 1.

Key Risk Stratification

The risk of neonatal HSV transmission depends on the mother's clinical status at delivery, not her partner's outbreak status:

• HSV-2 seropositive women with recurrent disease: ~1% transmission risk 2
• Primary first episode near delivery: 25-44% transmission risk 2
• The predominant risk is maternal genital shedding at delivery 1

When Suppressive Therapy IS Indicated in Pregnancy

Suppressive therapy should be offered in these specific situations:

1. Starting at 36 weeks gestation for women who had a first episode OR recurrence during the current pregnancy 3, 2, 4

   • Acyclovir 400 mg three times daily, OR
   • Valacyclovir 500 mg twice daily

2. Women with frequent, severe recurrences during pregnancy may warrant suppression 5

3. NOT for women with remote history and no pregnancy recurrences 2

Important Caveats

Partner outbreak status does not change maternal risk unless the woman herself is seronegative and at risk for primary acquisition. The scenario describes a woman with "history of HSV," indicating she is already infected. Her partner's outbreak does not increase her risk of neonatal transmission.

If she were HSV-seronegative (discordant couple), the recommendation would be different - she should avoid sexual contact during partner outbreaks and consider partner suppressive therapy to reduce transmission risk 6.

Practical Management Algorithm

For this pregnant woman:

• Counsel on avoiding sexual contact during partner's active outbreak 5
• Monitor for any maternal recurrences during pregnancy
• If she develops a recurrence: treat episodically with acyclovir (200 mg 5 times daily for 5-10 days) 2
• At 36 weeks: start suppressive therapy ONLY if she had a recurrence during this pregnancy 3, 2
• At delivery: examine carefully for lesions; cesarean delivery indicated only if active lesions or prodrome present 1

The evidence consistently shows that acyclovir suppression from 36 weeks reduces recurrences at delivery and cesarean rates 7, 4, 8, but this benefit applies to women who have demonstrated recurrent disease during the pregnancy, not those with remote history alone.